The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 5, 2013, Pages 562-573

  Compton, C ^a   McBryan, D ^a   Bucchioni, E ^a   Patalano, F ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Fixed dose combinations; Inflammation; Inhaled corticosteroids; Long acting bronchodilators; Once daily

Indexed keywords

ANTIINFLAMMATORY AGENT; BCT 197; BRONCHODILATING AGENT; CORTICOSTEROID; DILMAPIMOD; ELUBRIXIN; FLUTICASONE PROPIONATE; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; GSK 256066; INDACATEROL; MOMETASONE FUROATE; NAVARIXIN; PH 797804; PLACEBO; QMF 149; QVA 149; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHODILATATION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG ANTAGONISM; DRUG DELIVERY DEVICE; DRUG SAFETY; DYSPNEA; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEALTH CARE QUALITY; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; URINARY TRACT INFECTION; URINE RETENTION; XEROSTOMIA;

FIXED-DOSE COMBINATIONS; INFLAMMATION; INHALED CORTICOSTEROIDS; LONG-ACTING BRONCHODILATORS; ONCE-DAILY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; DRUG DESIGN; DRUG INDUSTRY; EXERCISE TOLERANCE; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

EID: 84882656351     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.05.009     Document Type: Article

References (146)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management and prevention of COPD. Updated 2013, Available from. http://www.goldcopd.org.
2. Cazzola M., Macnee W., Martinez F.J., Rabe K.F., Franciosi L.G., Barnes P.J., et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-469.
3. Niewoehner D.E., Wilt T.J. Inhaled corticosteroids for chronic obstructive pulmonary disease: a status report. Am J Respir Crit Care Med 2007, 175:103-104.
4. Cazzola M., Matera M.G. Emerging inhaled bronchodilators: an update. Eur Respir J 2009, 34:757-769.
5. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
6. Cazzola M., Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010, 23:257-267.
7. Dahl R., Chung K.F., Buhl R., Magnussen H., Nonikov V., Jack D., et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010, 65:473-479.
8. Donohue J.F., Fogarty C., Lotvall J., Mahler D.A., Worth H., Yorgancioglu A., et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010, 182:155-162.
9. Feldman G., Siler T., Prasad N., Jack D., Piggott S., Owen R., et al. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010, 10:11.
10. Kornmann O., Dahl R., Centanni S., Dogra A., Owen R., Lassen C., et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011, 37:273-279.
11. Chapman K.R., Rennard S.I., Dogra A., Owen R., Lassen C., Kramer B. Long-term safety and efficacy of indacaterol, a long-acting beta(2)-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011, 140:68-75.
12. Korn S., Kerwin E., Atis S., Amos C., Owen R., Lassen C. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011, 105:719-726.
13. Vogelmeier C., Ramos-Barbon D., Jack D., Piggott S., Owen R., Higgins M., et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res 2010, 11:135.
14. Beeh K.M., Wagner F., Khindri S., Drollmann A.F. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2011, 8:340-345.
15. O'Donnell D.E., Casaburi R., Vincken W., Puente-Maestu L., Swales J., Lawrence D., et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011, 105:1030-1036.
16. Wang J., Nie B., Xiong W., Xu Y. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther 2012, 37:204-211.
17. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San P.G., ZuWallack R.L., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002, 19:217-224.
18. Celli B., ZuWallack R., Wang S., Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003, 124:1743-1748.
19. Donohue J.F., van Noord J.A., Bateman E.D., Langley S.J., Lee A., Witek T.J., et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002, 122:47-55.
20. Niewoehner D.E., Rice K., Cote C., Paulson D., Cooper J.A., Korducki L., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005, 143:317-326.
21. O'Donnell D.E., Fluge T., Gerken F., Hamilton A., Webb K., Aguilaniu B., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004, 23:832-840.
22. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
23. Casaburi R., Briggs D.D., Donohue J.F., Serby C.W., Menjoge S.S., Witek T.J. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000, 118:1294-1302.
24. Vogelmeier C., Banerji D. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Ther Adv Respir Dis 2011, 5:163-173.
25. Abrams P., Andersson K.E., Buccafusco J.J., Chapple C., de Groat W.C., Fryer A.D., et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006, 148:565-578.
26. Sykes D.A., Dowling M.R., Leighton-Davies J., Kent T.C., Renard E., Trifilieff A., et al. The Influence of Receptor Kinetics on the Onset and Duration of Action, and the Therapeutic Index of NVA237 and Tiotropium. J Pharmacol Exp Ther 2012, 342:520-528.
27. Cooper N., Walker I., Knowles I. NVA237 has similar efficacy as tiotropium bromide against methacoline-induced bronchocostriction and less systemic effect on cardiovascular variables in an anaesthetized rabbit model. J Proc Am Thoracic Soc 2006, 3. A117.
28. Fogarty C., Hattersley H., Di S.L., Drollmann A. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2011, 105:337-342.
29. Verkindre C., Fukuchi Y., Flemale A., Takeda A., Overend T., Prasad N., et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010, 104:1482-1489.
30. Vogelmeier C., Verkindre C., Cheung D., Galdiz J.B., Guclu S.Z., Spangenthal S., et al. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 2010, 23:438-444.
31. D'Urzo A., Ferguson G.T., van Noord J.A., Hirata K., Martin C., Horton R., et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011, 12:156.
32. Kerwin E., Hebert J., Gallagher N., Martin C., Overend T., Alagappan V., et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study. Eur Resp J 2012, 40:1106-1114.
33. Partridge M.R., Karlsson N., Small I.R. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009, 25:2043-2048.
34. Small M., Broomfield M., Pollard R. Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler use and normal daily activities. Eur Resp J 2012, 40. Suppl. 56.
35. Witek T.J., Mahler D.A. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003, 21:267-272.
36. Beeh K., Singh D., Di Scala L. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012, 7:513-515.
37. Aizawa H., Inoue H., Ikeda T., Hirose T., Ito Y. Effects of procaterol, a beta-2-adrenoceptor stimulant, on neuroeffector transmission in human bronchial tissue. Respiration 1991, 58:163-166.
38. Rhoden K.J., Meldrum L.A., Barnes P.J. Inhibition of cholinergic neurotransmission in human airways by beta 2-adrenoceptors. J Appl Physiol 1988, 65:700-705.
39. Wessler I., Reinheimer T., Brunn G., Anderson G.P., Maclagan J., Racke K. Beta-adrenoceptors mediate inhibition of [3H]-acetylcholine release from the isolated rat and guinea-pig trachea: role of the airway mucosa and prostaglandins. Br J Pharmacol 1994, 113:1221-1230.
40. Carstairs J.R., Nimmo A.J., Barnes P.J. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis 1985, 132:541-547.
41. Mak J.C., Barnes P.J. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am Rev Respir Dis 1990, 141:1559-1568.
42. Tashkin D.P., Donohue J.F., Mahler D.A., Huang H., Goodwin E., Schaefer K., et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med 2009, 103:516-524.
43. Tashkin D.P., Pearle J., Iezzoni D., Varghese S.T. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009, 6:17-25.
44. van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Verhaert J., Disse B., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005, 26:214-222.
45. Mahler D.A., D'Urzo A., Bateman E.D., Ozkan S.A., White T., Peckitt C., et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012, 67:781-788.
46. D'Urzo A., Vogelmeier C. Future of chronic obstructive pulmonary disease management. Expert Rev Respir Med 2012, 6:285-299.
47. van Noord J.A., Buhl R., Laforce C., Martin C., Jones F., Dolker M., et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010, 65:1086-1091.
48. Van de M.B., Fabbri L.M., Martin C., Horton R., Dolker M., Overend T. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. COPD 2010, 7:418-427.
49. Banerji D., Chen H., Patalano F. The QVA149 IGNITE programme: dual bronchodilation as the future of COPD management. Prim Care Resp J 2012, 21. Abstract 179.
50. Bateman E., Ferguson G., Barnes N., Gallagher N. Benefits of dual bronchodilation with QVA149 once dailiy versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study. Eur Resp J 2012, 40:509s.
51. Vogelmeir C., Bateman E., Pallante J., Bryant H. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine 2013, 1:51-60.
52. Suissa S., Barnes P.J. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009, 34:13-16.
53. Beeh K.M., Korn S., Beier J., Jadayel D. QVA149 once daily improves exercise tolerance and lung function in patients with COPD: the BRIGHT study. Thorax 2012, 67. A147.
54. Wedzicha J., Decramer M., Ficker J., Niewoehner D.E., Sandstrom T., Fowler Taylor A., et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respiratory Medicine 2013, 1:199-209.
55. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000, 320:1297-1303.
56. Highland K.B., Strange C., Heffner J.E. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 2003, 138:969-973.
57. Pauwels R.A., Lofdahl C.G., Laitinen L.A., Schouten J.P., Postma D.S., Pride N.B., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999, 340:1948-1953.
58. Hakim A., Adcock I.M., Usmani O.S. Corticosteroid resistance and novel anti-inflammatory therapies in chronic obstructive pulmonary disease: current evidence and future direction. Drugs 2012, 72:1299-1312.
59. Calverley P., Pauwels R., Vestbo J., Jones P., Pride N., Gulsvik A., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361:449-456.
60. Celli B.R., Thomas N.E., Anderson J.A., Ferguson G.T., Jenkins C.R., Jones P.W., et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008, 178:332-338.
61. Barnes N.C., Qiu Y.S., Pavord I.D., Parker D., Davis P.A., Zhu J., et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006, 173:736-743.
62. Cazzola M., Dahl R. Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD. Chest 2004, 126:220-237.
63. Adcock I.M., Maneechotesuwan K., Usmani O. Molecular interactions between glucocorticoids and long-acting beta2-agonists. J Allergy Clin Immunol 2002, 110:S261-S268.
64. Doherty D.E., Tashkin D.P., Kerwin E., Knorr B.A., Shekar T., Banerjee S., et al. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis 2012, 7:57-71.
65. Karpel J.P., Busse W.W., Noonan M.J., Monahan M.E., Lutsky B., Staudinger H. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann Pharmacother 2005, 39:1977-1983.
66. Tashkin D.P., Doherty D.E., Kerwin E., Matiz-Bueno C.E., Knorr B., Shekar T., et al. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial. Int J Chron Obstruct Pulmon Dis 2012, 7:43-55.
67. Calverley P.M., Rennard S., Nelson H.S., Karpel J.P., Abbate E.H., Stryszak P., et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res 2008, 9:73.
68. Crim C., Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009, 34:641-647.
69. Beasley R., Lanier B., Mark Z., Moton A. Long-term efficacy of QMF149 in persistent asthma. Eur Resp J 2012, 40:312s.
70. Beasley R., Lanier B., Mark Z., Moton A. Safety of once-daily QMF149 in patients with persistent asthma. Eur Resp J 2012, 40:371s.
71. ClinicalTrials.gov. Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD). Available from: http://www.clinicaltrial.gov/ct2/show/NCT01636076%3Fterm%3DQMF149+COPD&rank%3D1.
72. ® in healthy volunteers. Eur Resp J 2012, 40:382s.
73. Terzano C. Dry powder inhalers and the risk of error. Respiration 2008, 75:14-15.
74. Wieshammer S., Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors?. Respiration 2008, 75:18-25.
75. Al-Showair R.A., Tarsin W.Y., Assi K.H., Pearson S.B., Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?. Respir Med 2007, 101:2395-2401.
76. Janssens W., VandenBrande P., Hardeman E., De Langhe E., Philps T., Troosters T., et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J 2008, 31:78-83.
77. Chapman K.R., Fogarty C.M., Peckitt C., Lassen C., Jadayel D., Dederichs J., et al. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis 2011, 6:353-363.
78. Pavkov R., Mueller S., Fiebich K., Singh D., Stowasser F., Pignatelli G., et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin 2010, 26:2527-2533.
79. Byron P.R. Drug delivery devices: issues in drug development. Proc Am Thorac Soc 2004, 1:321-328.
80. United States Pharmacopeial Convention Aerosols, metered dose inhalers, and dry powder inhalers 2009, In: USP30-NF25.
81. Colthorpe P., Voshaar T., Cuoghi E., Kieckbusch T., Jauernig J. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. JDA 2013, 2:11-16.
82. Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003, 22:672-688.
83. Witko-Sarsat V., Halbwachs-Mecarelli L., Schuster A., Nusbaum P., Ueki I., Canteloup S., et al. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol 1999, 20:729-736.
84. Hashimoto S., Kobayashi A., Kooguchi K., Kitamura Y., Onodera H., Nakajima H. Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome. Am J Respir Crit Care Med 2000, 161:237-243.
85. Majo J., Ghezzo H., Cosio M.G. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 2001, 17:946-953.
86. Russell R.E., Thorley A., Culpitt S.V., Dodd S., Donnelly L.E., Demattos C., et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol 2002, 283:L867-L873.
87. O'Shaughnessy T.C., Ansari T.W., Barnes N.C., Jeffery P.K. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997, 155:852-857.
88. Snoeck-Stroband J.B., Postma D.S., Lapperre T.S., Gosman M.M., Thiadens H.A., Kauffman H.F., et al. Airway inflammation contributes to health status in COPD: a cross-sectional study. Respir Res 2006, 7:140.
89. Stanescu D., Sanna A., Veriter C., Kostianev S., Calcagni P.G., Fabbri L.M., et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996, 51:267-271.
90. Aaron S.D., Angel J.B., Lunau M., Wright K., Fex C., Le S.N., et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163:349-355.
91. Bhowmik A., Seemungal T.A., Sapsford R.J., Wedzicha J.A. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000, 55:114-120.
92. Crooks S.W., Bayley D.L., Hill S.L., Stockley R.A. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000, 15:274-280.
93. Agusti A., Edwards L.D., Rennard S.I., Macnee W., Tal-Singer R., Miller B.E., et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012, 7. e37483.
94. Bon J.M., Leader J.K., Weissfeld J.L., Coxson H.O., Zheng B., Branch R.A., et al. The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PLoS One 2009, 4. e6865.
95. Pinto-Plata V., Casanova C., Mullerova H., de Torres J.P., Corado H., Varo N., et al. Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD. Respir Res 2012, 13:71.
96. Agusti A.G., Noguera A., Sauleda J., Sala E., Pons J., Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:347-360.
97. Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580.
98. Essayan D.M. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001, 108:671-680.
99. Grootendorst D.C., Gauw S.A., Verhoosel R.M., Sterk P.J., Hospers J.J., Bredenbroker D., et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007, 62:1081-1087.
100. Martorana P.A., Beume R., Lucattelli M., Wollin L., Lungarella G. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005, 172:848-853.
101. UK Medicine Information (UKMi) New Drugs Online, Roflumilast. Available from: http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID%3D3320.
102. Calverley P.M., Sanchez-Toril F., McIvor A., Teichmann P., Bredenbroeker D., Fabbri L.M. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176:154-161.
103. Calverley P.M., Rabe K.F., Goehring U.M., Kristiansen S., Fabbri L.M., Martinez F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694.
104. Fabbri L.M., Calverley P.M., Izquierdo-Alonso J.L., Bundschuh D.S., Brose M., Martinez F.J., et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009, 374:695-703.
105. Rabe K.F., Bateman E.D., O'Donnell D., Witte S., Bredenbroker D., Bethke T.D. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005, 366:563-571.
106. Rennard S.I., Calverley P.M., Goehring U.M., Bredenbroker D., Martinez F.J. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 2011, 12:18.
107. Calverley P.M., Martinez F.J., Fabbri L.M., Goehring U.M., Rabe K.F. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol. Int J Chron Obstruct Pulmon Dis 2012, 7:375-382.
108. Cazzola M., Page C.P., Calzetta L., Matera M.G. Emerging anti-inflammatory strategies for COPD. Eur Respir J 2012, 40:724-741.
109. Nials A.T., Tralau-Stewart C.J., Gascoigne M.H., Ball D.I., Ranshaw L.E., Knowles R.G. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2011, 337:137-144.
110. ClinicalTrials.gov. Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00549679?term%3DGSK256066&rank%3D5.
111. Danto s, Wei G.S., Gill J. A randomized, double-blind, placebo-controlled, six-week study of the efficacy and safety of tofimilast dry powder for inhalation in adults with COPD. Am J Respr Crit Care Med 2007, 175. A131.
112. Bardin P.G., Dorward M.A., Lampe F.C., Franke B., Holgate S.T. Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen. Br J Clin Pharmacol 1998, 45:387-391.
113. Boswell-Smith V., Spina D., Oxford A.W., Comer M.B., Seeds E.A., Page C.P. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6, 7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquino lin-4-one]. J Pharmacol Exp Ther 2006, 318:840-848.
114. Biortfolio Article. Available from: http://www.bioportfolio.com/news/article/1155499/Verona-Pharma-Reports-Bronchodilator-Data-With-Rpl554-In-Copd-Patients-At-The.html.
115. Ferrari N., Seguin R., Renzi P. Oligonucleotides: a multi-targeted approach for the treatment of respiratory diseases. Future Med Chem 2011, 3:1647-1662.
116. Di S.A., Caramori G., Gnemmi I., Contoli M., Bristot L., Capelli A., et al. Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD. Thorax 2009, 64:968-975.
117. Yamamoto C., Yoneda T., Yoshikawa M., Fu A., Tokuyama T., Tsukaguchi K., et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997, 112:505-510.
118. Qiu Y., Zhu J., Bandi V., Atmar R.L., Hattotuwa K., Guntupalli K.K., et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 168:968-975.
119. Holz O., Khalilieh S., Ludwig-Sengpiel A., Watz H., Stryszak P., Soni P., et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010, 35:564-570.
120. Lazaar A.L., Sweeney L.E., MacDonald A.J., Alexis N.E., Chen C., Tal-Singer R. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 2011, 72:282-293.
121. Nair P., Gaga M., Zervas E., Alagha K., Hargreave F.E., O'Byrne P.M., et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 2012, 42:1097-1103.
122. ClinicalTrials.gov. Long-Term Extension Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD (P05575AM2)(MK-7123-009-0). Available from: http://www.clinicaltrials.gov/ct2/show/NCT01006616%3Fterm%3DSCH527123&rank%3D7.
123. Wijtmans M., Verzijl D., Leurs R. de E, I, Smit MJ. Towards small-molecule CXCR3 ligands with clinical potential. Chem Med Chem 2008, 3:861-872.
124. Zhang J., Patel J.M. Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases. Int J Clin Exp Med 2010, 3:233-244.
125. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912.
126. Gaffey K., Reynolds S., Plumb J., Kaur M., Singh D. Increased phosphorylated p38 mitogen activated protein kinase in COPD lungs. Eur Respir J 2012, In Press.
127. Renda T., Baraldo S., Pelaia G., Bazzan E., Turato G., Papi A., et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008, 31:62-69.
128. Smith S.J., Fenwick P.S., Nicholson A.G., Kirschenbaum F., Finney-Hayward T.K., Higgins L.S., et al. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 2006, 149:393-404.
129. Underwood D.C., Osborn R.R., Bochnowicz S., Webb E.F., Rieman D.J., Lee J.C., et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 2000, 279:L895-L902.
130. Heuertz R.M., Tricomi S.M., Ezekiel U.R., Webster R.O. C-reactive protein inhibits chemotactic peptide-induced p38 mitogen-activated protein kinase activity and human neutrophil movement. J Biol Chem 1999, 274:17968-17974.
131. Langlois A., Chouinard F., Flamand N., Ferland C., Rola-Pleszczynski M., Laviolette M. Crucial implication of protein kinase C (PKC)-delta, PKC-zeta, ERK-1/2, and p38 MAPK in migration of human asthmatic eosinophils. J Leukoc Biol 2009, 85:656-663.
132. Huot J., Houle F., Marceau F., Landry J. Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Circ Res 1997, 80:383-392.
133. Larsen J.K., Yamboliev I.A., Weber L.A., Gerthoffer W.T. Phosphorylation of the 27-kDa heat shock protein via p38 MAP kinase and MAPKAP kinase in smooth muscle. Am J Physiol 1997, 273:L930-L940.
134. Li F., Zhang M., Hussain F., Triantaphyllopoulos K., Clark A.R., Bhavsar P.K., et al. Inhibition of p38 MAPK-dependent bronchial contraction after ozone by corticosteroids. Eur Respir J 2011, 37:933-942.
135. Chung K.F. p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011, 139:1470-1479.
136. Hall D.J., Bates M.E., Guar L., Cronan M., Korpi N., Bertics P.J. The role of p38 MAPK in rhinovirus-induced monocyte chemoattractant protein-1 production by monocytic-lineage cells. J Immunol 2005, 174:8056-8063.
137. Hayashi S., Jibiki I., Asai Y., Gon Y., Kobayashi T., Ichiwata T., et al. Analysis of gene expression in human bronchial epithelial cells upon influenza virus infection and regulation by p38 mitogen-activated protein kinase and c-Jun-N-terminal kinase. Respirology 2008, 13:203-214.
138. Leigh R., Oyelusi W., Wiehler S., Koetzler R., Zaheer R.S., Newton R., et al. Human rhinovirus infection enhances airway epithelial cell production of growth factors involved in airway remodeling. J Allergy Clin Immunol 2008, 121:1238-1245.
139. Singh D., Smyth L., Borrill Z., Sweeney L., Tal-Singer R. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol 2010, 50:94-100.
140. Barnes P., Pavord I., Maden C. Evaluation of an oral p38 mitogen-activated kinase inhibitors SB-681323 in COPD. Eur Resp J 2009, 34:648.
141. MacNee V., Allan R., Jones I. A randomized, placebo controlled trial of 6 weeks treatment with a novel oral p38 inhibitor in patients with COPD. Eur Resp J 2010, 36:718.
142. ClinicalTrials.gov. An Exploratory, Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Efficacy, Safety and Tolerability of a Single and a Repeated Dose of Oral BCT197 in Patients With an Acute COPD Exacerbation. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01332097%3Fterm%3DBCT197+copd&rank%3D1.
143. Chopra P., Kanoje V., Semwal A., Ray A. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin Investig Drugs 2008, 17:1411-1425.
144. Agusti A.G. COPD, a multicomponent disease: implications for management. Respir Med 2005, 99:670-682.
145. Han M.K., Agusti A., Calverley P.M., Celli B.R., Criner G., Curtis J.L., et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010, 182:598-604.
146. Barnes P.J. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010, 19:330-338.